Journal
DRUG TESTING AND ANALYSIS
Volume 6, Issue 7-8, Pages 764-769Publisher
WILEY
DOI: 10.1002/dta.1522
Keywords
designer drugs; 25B-MBOMe; HPLC-MS/MS; bath salts; overdose
Funding
- National Institute of Drug Abuse (NIDA) Center for Drug Abuse [P50DA005274]
Ask authors/readers for more resources
We present a case of 4-bromo-2,5-dimethoxy-N-[(2-methoxyphenyl)methyl]-benzeneethanamine (25B-NBOMe), an N-benzyl phenethylamines derivative, intoxication and a high performance liquid chromatography with tandem mass spectrometry (HPLC-MS/MS) method for detection and quantification of 25B-NBOMe. A 19-year-old male was found unresponsive with generalized grand mal seizure activity. On the second day of hospitalization, a friend admitted that the patient used 'some unknown drug' called 25B. Serum and urine collected we resent to the Virginia Commonwealth University Medical Center Toxicology Laboratory for analysis. An HPLC-MS/MS method for the identification and quantification of 25B-NBOMe using 2-(2,5-dimethoxyphenyl)-N-(2-methoxybenzyl) ethanamine(25H-NBOMe) as the internal standard (ISTD) was developed. As this isanovel, single-casepresentation, an assay validation was performed prior to testing to ensure the reliability of the analytical results. The serum and urine specimens were determined to contain 180 pg/ml and1900 pg/ml of 25B-NBOMe, respectively. Copyright (C) 2013 John Wiley & Sons, Ltd.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available